SSSachin J. Shah

Sachin J. Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sachin J. Shah has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Temporal Validation and Simplification of Mortality Prediction for Perioperative Cardiopulmonary Resuscitation

    by Lucy Chen, Samuel Justice, Siva Muthupalaniappan, Sachin J. Shah, Matthew B. Allen

    Background: Perioperative cardiac arrest is associated with high mortality, but population-level estimates of outcomes after perioperative cardiopulmonary resuscitation (CPR) do not account for differences in risk among individual patients. We previously developed the CPR OutcoMes Prediction for Arrest in Surgical Settings (COMPASS) model to estimate 30-day mortality after cardiac arrest requiring CPR on the day of surgery. The model incorporates 33 preoperative predictors and has not been evaluated in a temporally distinct cohort. We therefore sought to temporally validate COMPASS and to develop and temporally validate a simplified point-based mortality score. Methods: We performed a retrospective prognostic study of adults undergoing noncardiac surgery who experienced cardiac arrest requiring CPR on postoperative day 0 in the American College of Surgeons National Surgical Quality Improvement Program. The primary outcome was 30-day mortality. The published COMPASS model, developed using 2012–2023 data, was applied without refitting to the 2024 cohort. A simplified point-based score was developed in the 2012–2023 cohort and temporally validated in 2024. Performance was assessed using discrimination, calibration, and Brier score. Results: The 2024 temporal validation cohort included 429 patients, of whom 274 (63.9%) died within 30 days. The COMPASS model had an area under the receiver operating characteristic curve (AUROC) of 0.82 (95% CI, 0.78–0.86), calibration intercept of 0.24, calibration slope of 1.10, and Brier score of 0.17. The simplified 3-variable score incorporating age, American Society of Anesthesiologists physical status, and case urgency had an AUROC of 0.81 (95% CI, 0.77–0.86), calibration intercept of 0.19, calibration slope of 1.25, and Brier score of 0.17. Conclusions: In a temporally distinct cohort, the published COMPASS model retained predictive performance for 30-day mortality after perioperative CPR. The simplified score showed similar performance. These findings support further evaluation of both approaches as tools for individualized estimation of perioperative CPR mortality.

  • Open Access

    Clinical and Decisional Trajectories Preceding Early Postprocedural Death Among Patients with Preexisting Code-Status Limitations

    by Matthew B. Allen, Jocelyn L Streid, Elizabeth J Lilley, Christine S Ritchie, Christy E Cauley, Jason N Batten, Rachelle E Bernacki, Amanda J Reich, Preeti R John, David L Hepner, et al.

    Objective: To develop a typology of recurrent clinical and decisional trajectories preceding early postprocedural death among patients with preexisting code-status limitations. Background: Patients with do-not-resuscitate orders experience higher postoperative mortality, but the clinical and decisional processes underlying early deaths are poorly understood. Mortality and code status alone cannot determine whether these deaths reflect constrained rescue, unsuccessful treatment, progression of terminal illness, or reassessment-driven redirection of care. Methods: We conducted a retrospective qualitative trajectory analysis of electronic health record documentation across five academic and community hospitals from March 2024 through June 2025. Eligible adults had an active preprocedural code-status limitation and died within 3 calendar days of a procedure requiring anesthesia, before hospital discharge. Using an adapted sequence-based composite approach, 2 reviewers independently reconstructed cases as ordered clinical and decisional sequences and reached consensus on recurrent trajectory families; illustrative composites were then generated. A third reviewer independently classified cases while blinded to the consensus assignments; agreement was assessed using unweighted Cohen kappa. Results: Among 2,833 patients with preexisting code-status limitations who underwent a procedure, 44 (1.6%) died within 3 days; the 42 who died before hospital discharge were included. Four trajectory families were identified: established terminal trajectory (5 [12%]), abrupt terminal event (5 [12%]), comfort-focused redirection after reassessment (29 [69%]), and sustained rescue attempt (3 [7%]). Redirection followed progressive deterioration or persistent critical illness despite treatment in 20 cases and a discrete event or finding in 9; rescue-oriented treatment frequently continued or escalated before reassessment and redirection. In sustained-rescue trajectories, intensive treatment continued through death, including in 2 patients whose limitations on CPR remained in effect. The independent reviewer agreed with the consensus classification for 39 of 42 cases (92.9%; κ, 0.86; 95% CI, 0.70-1.00). Conclusions: Early postprocedural deaths among patients with preexisting code-status limitations followed distinct clinical and decisional trajectories. Mortality and code status alone could not distinguish an established terminal trajectory, abrupt death, reassessment-driven redirection, or sustained but unsuccessful rescue. A longitudinal approach that considers procedural intent, evolving prognosis, treatment, and reassessment provides a more clinically meaningful basis for interpreting mortality and structuring perioperative decision making.

  • Perioperative Continuation of Code-status Limitations and Early Postoperative Mortality

    by Matthew B. Allen, Jocelyn L. Streid, Elizabeth J. Lilley, Christy E. Cauley, Rachelle E. Bernacki, Amanda J. Reich, Preeti R. John, David L. Hepner, Angela M. Bader, Sachin J. Shah

    Objective: The objective of this study was to determine whether perioperative continuation of code status limitations is associated with early postoperative mortality and to characterize postoperative code-status trajectories preceding early deaths. Summary Background Data: Decisions about perioperative management of do-not-resuscitate (DNR) orders are common, yet their relationship to early postoperative outcomes remains poorly understood. Methods: This was a retrospective cohort study conducted from March 2024 to June 2025 across 5 hospitals within a single academic health system. We included adults aged 18 years or older who presented for a procedure under anesthesia with a code status other than full code. The exposure was perioperative code status (reversal to full code vs. not full code). The primary outcome was all-cause mortality within 3 days of the procedure. The secondary outcome was use of invasive hemodynamic monitoring. Associations were estimated using multivariable logistic regression. Results: Among 2833 eligible patients, none were excluded. The median age was 79 years (IQR, 70–86), and 59% were women. Of 2833 patients, 2323 (82%) reversed to full code perioperatively, and 510 (18%) remained not full code. Forty-four patients (1.6%) died within 3 days. Three-day mortality occurred in 15 of 510 patients (2.9%) who remained not full code and in 29 of 2,323 patients (1.2%) who reversed to full code. After adjustment for age, sex, ASA physical status, operative stress score, and race, not full code status was associated with higher odds of 3-day mortality (adjusted odds ratio, 2.18; 95% CI, 1.14–4.16), corresponding to an adjusted absolute risk difference of 1.43% (95% CI, 0.06%–2.95%). Among patients who died within 3 days and remained hospitalized, 34 of 42 (81%) died after transition to comfort-focused care. Invasive hemodynamic monitoring was more common among patients who remained not full code (adjusted absolute risk difference, 3.74%; 95% CI, 0.91%–6.93%). Conclusions: Among adults presenting for a procedure with code-status limitations, continuation of a nonfull code status was associated with higher early postoperative mortality. This pattern reflects downstream clinical trajectories and treatment decisions rather than missed opportunities for perioperative rescue.

  • Open Access

    Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial

    by Shao-Wei Lo, Darae Ko, Dae Hyun Kim, Long H. Ngo, Daniel E Singer, Sachin J Shah

    Background: It is uncertain if anticoagulants provide a net benefit in subclinical AF (SCAF). The ARTESIA trial showed apixaban reduced the relative hazard of stroke/systemic embolism (SSE) in SCAF, but did not report absolute risk reduction (ARR). The reported Kaplan-Meier analysis did not account for the competing risk of death or 24-hour AF events. We reanalyzed ARTESIA accounting for competing risks to determine the ARR of apixaban vs. aspirin. Methods: Individual time-to-event and time-to-censoring data were extracted from the published Kaplan-Meier curve. ARTESIA classified deaths and 24-hour AF events as censoring events. We probabilistically reclassified them to competing events to estimate the ARR. We used the Aalen-Johansen estimator to estimate the cumulative risk of stroke/systemic embolism at 3.5 years, accounting for competing events. We compared these results to the Kaplan-Meier estimator. Result: After reclassification of deaths and 24-hour AF to competing events, there were 1111 censoring and 852 competing events in the apixaban arm, and 1100 censoring and 816 competing events in the aspirin arm. Compared to the Aalen-Johansen estimator, the Kaplan-Meier estimator overestimated the cumulative SSE risk at 3.5 years with apixaban (2.64% vs. 2.20%, difference in estimates 0.43 percentage points; 95% CI 0.27 to 0.62) and with aspirin (4.58% vs. 3.82%, difference in estimates 0.76 percentage points; 95% CI 0.56 to 1.01). Compared to the Aalen-Johansen estimator, the Kaplan-Meier estimator overestimated the ARR of SSE risk at 3.5 years with apixaban compared to aspirin (1.94% vs. 1.61%, difference in estimates 0.33 percentage points; 95% CI, 0.06 to 0.64). Conclusion: In SCAF, apixaban reduced the 3.5-year risk of SSE by 1.61%, which would be overestimated by 20% if death and >24-hour AF events are treated as censoring rather than competing events.

  • Open Access

    Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab

    by Sarah F. Ackley, Michael Flanders, Audrey Murchland, Ruijia Chen, Jingxuan Wang, Sachin J. Shah, Edward D. Huey, M. Maria Glymour

    Background Amyloid removal has been used as a surrogate outcome in Alzheimer’s disease trials, allowing accelerated approval of aducanumab and lecanemab. The A4 (Alzheimer’s Clinical Trial Consortium A4/LEARN) trial’s individual-level data supports novel methods to evaluate amyloid’s validity as a surrogate for cognitive decline. Methods In 812 participants, cognitive and functional change was measured using the CDR-SB score. Instrumental-variable analysis estimated the effect of amyloid reduction; mediation analysis quantified solanezumab’s cognitive effect mediated by amyloid reduction. Results Each 10 centiloid reduction due to randomization to treatment was associated with 0.026 higher CDR-SB (95% CI: -0.013, 0.065) 14.6% of solanezumab’s effect on cognition was mediated by amyloid reduction (95% CI: –122%, 208%). Discussion Estimates showing near-zero effects of amyloid reduction on cognitive decline suggest minimal impact of amyloid reduction in populations with little disease progression. Replication in anti-amyloid trials with larger treatment effects could guide treatment and regulatory decisions.

  • Open Access

    Rates of new indication for antithrombotic drugs in people with cognitive impairment: implications for anti-amyloid monoclonal antibody treatment

    by Anna L Parks, Jacquelyn M Lykken, Meghan L Rieu-Werden, Darae Ko, Dae Hyun Kim, Margaret C Fang, Steven M Greenberg, Daniel M Witt, Mark A Supiano, Sachin J Shah

    Objectives Antithrombotic drugs—anticoagulants and thrombolytics— may interact with anti-amyloid monoclonal antibodies (mAbs) to increase intracranial hemorrhage risk, so expert guidance recommends against their co-prescription. We aimed to estimate how many people with mild cognitive impairment (MCI) or dementia develop a new cardiovascular indication for antithrombotic drugs. Methods In a longitudinal cohort of adults ≥65 years old from the Health and Retirement Study (2010-2020) with linked Medicare claims and no prior indication for anticoagulants, cognition was categorized as normal, MCI, or dementia. We fit Fine-Gray separate survival models accounting for competing risk of death to estimate 1-year incidence of atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE), acute myocardial infarction (MI), and stroke. Results Among 12,373 participants (mean age 73 years, 59% female), for MCI, 1-year incidence was 1.7% for AF, 1.2% for DVT, 0.4% for PE, 1.2% for AMI, 2.0% for stroke, and 5.7% for any indication. In dementia, 1-year rates were 1.7% for AF, 1.8% for DVT, 0.3% for PE, 1.0% for AMI, 2.4% for stroke, and 6.7% for any indication. Discussion Our finding inform shared decision-making about the tradeoffs of anti-amyloid mAbs.

  • Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial

    by Sachin J. Shah, Jay M. Iyer, Leila Agha, Yuchiao Chang, Jeffrey M. Ashburner, Steven J. Atlas, David D. McManus, Patrick T. Ellinor, Steven A. Lubitz, Daniel E. Singer

    BACKGROUND: One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches. METHODS: The VITAL-AF trial was a cluster-randomized trial of 1-time, 30-second single-lead ECG screening during primary care visits. It enrolled adults aged ≥65 years in 16 Massachusetts General Hospital primary care practices (2018–2019). In this secondary analysis, we tested 2 approaches to identify subgroups where screening is effective. First, we developed an effect-based model using T-learner, a causal inference approach that estimates screening effects by separately training 2 predictive models—one for screening and one for usual care—and then compares their predictions for each individual. Second, we used a validated AF risk model (Cohorts for Heart and Aging Research in Genomic Epidemiology AF) to test for heterogeneous screening effectiveness. We assessed AF screening effectiveness by quartile of predicted effect and predicted AF risk and determined their correlation. RESULTS: The study included 29 656 participants (mean±SD age 74±7 years, 59% women). In the highest quartile of predicted screening effect, AF diagnosis rates were higher in the screening versus the usual care group (4.00 versus 2.88 per 100 person-years, rate difference 1.12 [95% CI, 0.11–2.13] per 100 person-years). In the highest quartile of predicted AF risk, AF diagnosis rates were also higher in the screening versus the usual care group (5.55 versus 4.23 per 100 person-years, rate difference 1.32 [95% CI, 0.14–2.50] per 100 person-years). Predicted screening effect and predicted AF risk were weakly correlated (Spearman correlation coefficient, 0.23). CONCLUSIONS: One-time screening was associated with increased AF diagnoses in the top quartile of both predicted screening effect and predicted AF risk. Because predicted effect and risk were only weakly correlated, future AF screening efforts should include both high-effect and high-risk individuals.


  • Open Access

    Lecanemab and Anticoagulants: Projected Effects on Health and Quality of Life

    by Sachin J. Shah, Tai Dinger, Deborah Blacker, Steven M. Greenberg, John C. Giardina, Jacquelyn M. Lykken, Samhita Kalidindi, Livia Qoshe, Joseph P. Newhouse, Ankur Pandya, et al.

    Background: Lecanemab slows cognitive decline among people with early Alzheimer’s disease (early AD) but appears to increase the risk of intracranial hemorrhages (ICHs), including anticoagulant-related ICHs. Objective: To examine the benefits and harms of co-prescribing lecanemab and anticoagulants in people with atrial fibrillation (AF) experiencing early AD. Design: Microsimulation model to compare four treatment strategies. Using inputs from the literature, we modeled increased ICH risk with lecanemab (2.02-fold), apixaban (1.84-fold), and lecanemab/apixaban interaction (2.67-fold). We assigned quality-of-life estimates and increased mortality risk with cognitive decline, stroke, and ICH. Data Sources: Clinical trials, observational cohorts Target Population: People 65-90 years with AF and early AD Time Horizon: 18-month Intervention: Apixaban ( APIX ), apixaban and lecanemab ( APIX/LEC ), lecanemab ( LEC ), neither Outcome Measures: ICH, ischemic stroke, cognitive decline, quality-adjusted life months (QALMs), and survival, age-stratified. Results of Base Case: For 100,000 simulated persons aged 65-74 years, APIX , APIX/LEC , and LEC would result in a similar clinical benefit (13.2 QALMs). Compared to APIX , APIX/LEC would result in more ICH events (1,990 vs. 400), all-cause deaths (5,820 vs. 5,140), but slower cognitive decline (mean CDR-SB change, 1.11 vs. 1.53). For persons ≥75 years, APIX alone would always be preferred. Results of Sensitivity Analysis: Results are sensitive to lecanemab-anticoagulant interaction on ICH, baseline ICH risk, and lecanemab’s effect on cognition. Limitations: Significant parameter uncertainty; treatment burden and costs were not modeled. Conclusions: Model-based results support anticoagulants alone as the preferred strategy for people ≥75 years with early AD and AF. There was greater equipoise across treatment strategies for persons 65-74 years, for whom improved estimates of the ICH risk and lecanemab-anticoagulant interaction are critical to identifying the preferred strategy. Primary Funding Source: National Institute on Aging/National Institutes of Health (K76AG074919, P30AG062421, U01AG076478, and R01AG069575).

  • A qualitative study of people with Alzheimer’s disease in a memory clinic considering lecanemab treatment

    by Anna L Parks, Ayush Thacker, Daniel Dohan, Liliana A Ramirez Gomez, Christine S Ritchie, Joanna Paladino, Sachin J Shah

    Background: People with Alzheimer's disease (AD) now have access to disease-modifying treatment with anti-amyloid monoclonal antibodies (mAbs). Their perception of risks and benefits and approach to treatment decisions remain unknown. Objective: We aimed to understand how people with AD weigh the benefits and costs of anti amyloid mAbs and incorporate these into decisions about treatment. Methods: We conducted semi-structured interviews with people with biomarker- or imaging-confirmed AD and mild or moderate cognitive impairment who were seen at memory care clinics and discussed lecanemab with a clinician. Interviews were recorded, transcribed, and deidentified. Thematic analysis identified themes and subthemes. Results: Among 22 participants (mean age 70, 8 [36%] women, 22 [100%] White), analysis revealed 3 major themes and associated subthemes: (1) People with AD sought and obtained information from different sources—advocacy organizations, the Internet, and clinicians; (2) Hopes, expected benefits, and the existential threat of dementia drove willingness and readiness to start lecanemab; (3) Individual traits, family factors, and degree of trust in expertise influenced how people balanced risks and benefits. Some would accept treatment at any cost; others carefully weighed risks and burdens, but were motivated by supportive families, insurance coverage, and trust in expertise; for a few, costs decidedly outweighed their personal benefits. People with AD desired more individualized information and to hear more from patients who took the medication. Conclusions: Results from this first qualitative study of people with AD considering treatment with anti-amyloid mAbs can inform clinician, health system and policy efforts to individualize decisions.


  • The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment

    by Sachin J Shah, Christopher R Manz, Brendan Balthis, Hari S Raman, Jason Abaluck, Nancy L Keating, Leila Agha

    Representative trials are critical to advancing cancer treatment, yet little is known about how geographic siting contributes to nonrepresentative enrollment. Using patient-level data, we determined how the choice of trial-enrolling regions and practices impacts representativeness. We created a Surveillance, Epidemiology, and End Results–Medicare cohort of people aged 65 years and older with lung, breast, pancreatic, or renal cancer (2014-2019). We identified randomized cancer drug trial participants and determined their prevalence by advanced age (those aged 75 years and older), sex, race, ethnicity, and rural residence in the full cohort, trial-enrolling regions, trial-enrolling practices, and trials. The choice of region and practice contributed to more than 50% of the underenrollment of Black, Hispanic, and rural patients. Cancer trials enrolled 45% fewer Black patients than expected with proportional representation. Trial recruitment in regions and practices with proportionately fewer Black patients accounted for 27% and 35% of this disparity, respectively. These findings suggest that diversifying cancer trials requires changing the regions and practices referring and enrolling patients.